Short answer
Vera Therapeutics, Inc. (VERA) filed an 8-K current report with the SEC on March 9, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Christopher Hite appointed to Board as Class III Director effective March 5, 2026; term expires at 2027 Annual Meeting.
Vera Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Christopher Hite appointed to Board as Class III Director effective March 5, 2026; term expires at 2027 Annual Meeting
- Initial option grant: 24,937 shares at $38.85/share, vesting monthly over 3 years
- Annual cash retainer $45,000, pro-rated for 2026
- Annual option grants from 2027 onward capped at 18,000 shares or $400,000 fair value, whichever is lower
- No disclosed arrangements or related-party transactions tied to appointment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Vera Therapeutics, Inc. 8-K filings
Get the next VERA 8-K as it lands
Follow VERA for push alerts, or ask the research agent what this filing means.